🇺🇸 FTY720 in United States

59 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blood Creatinine Increased — 15 reports (25.42%)
  2. Hypotension — 6 reports (10.17%)
  3. Kidney Transplant Rejection — 6 reports (10.17%)
  4. Pyrexia — 6 reports (10.17%)
  5. Dyspnoea — 5 reports (8.47%)
  6. Vomiting — 5 reports (8.47%)
  7. Disease Progression — 4 reports (6.78%)
  8. Drug Ineffective — 4 reports (6.78%)
  9. Graft Dysfunction — 4 reports (6.78%)
  10. Nephropathy Toxic — 4 reports (6.78%)

Source database →

FTY720 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in United States

Frequently asked questions

Is FTY720 approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for FTY720 in United States?

Novartis Pharmaceuticals is the originator. The local marketing authorisation holder may differ — check the official source linked above.